According to a notification by the US Food and Drug Administration (FDA), the recall of the 19,536 bottles has been voluntarily initiated by the company through its US-based arm Zydus Pharmaceuticals USA Inc.
The recall has been initiated by the company on December 23 and has been initiated under Class-II, which FDA states as a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences.
The capsules were manufactured by Cadila Healthcare and distributed in the US by Zydus Pharmaceuticals USA Inc.
Comments from the company could not be obtained immediately.
Earlier, Zydus Pharmaceuticals USA Inc had initiated a voluntary recall for 58,920 bottles of benzonatate capsules on November 26 for failing to meet specifications.
Headquartered in Ahmedabad, Zydus Cadila group has global operations in four continents spread across USA, Europe, Japan, Brazil, South Africa and 25 other emerging markets.
The group's operations range from active pharmaceutical ingredients (API) to formulations, animal health products and 'cosmeceuticals'.
Shares in Cadila Healthcare, on Thursday, ended at Rs 1,652.45 apiece on the BSE, up 0.13 per cent from the previous close.